

**Product Name** : Rigosertib

**Synonyms** : ON-01910

Cat No. M24584

**CAS Number** 592542-59-1

Molecular Formula : C21H25NO8S

: 451.5 Formula Weight

**Chemical Name** 

Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a Description

: selective anti-cancer agent, which induces apoptosis by inhibition of the PI3 kinase/Akt pathway, promotes the

phosphorylation of histone H2AX and induces G2/M arrest in the cell cycle.

**Pathway** : Apoptosis

**Target** : Apoptosis

Receptor : Apoptosis;BCR-ABL;Cdk1;Flt1;Fyn;PDGFR;PLK1;PLK2;Src

: DMSO:75 mg/mL (166.12 mM; Need ultrasonic) Solubility

 $: \quad \mathsf{COC1} = \mathsf{C}(\mathsf{C} = \mathsf{C}(\mathsf{C} = \mathsf{C1})\mathsf{CS}(= \mathsf{O})(= \mathsf{O})/\mathsf{C} = \mathsf{C}/\mathsf{C2} = \mathsf{C}(\mathsf{C} = \mathsf{C2OC})\mathsf{OC})\mathsf{OC})\mathsf{NCC}(= \mathsf{O})\mathsf{OC}(\mathsf{C1}) = \mathsf{C1}(\mathsf{C1}) = \mathsf{C1}(\mathsf$ **SMILES** 

: (-20℃) Storage

Stability : ≥2 years

Reference

1.Xu F, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310.